Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer by 
The outcome of patients with non-operable metastatic colorectal
cancer remains poor. Four meta-analyses previously performed by
the Meta-Analysis Group In Cancer confirmed that the effect of
intravenous bolus 5-fluorouracil (5FU) can be increased by the
modulation of 5FU by leucovorin (Advanced Colorectal Cancer
Meta-analysis Project 1992) or by methotrexate (Advanced
Colorectal Cancer Meta-analysis Project 1994), the administration
of 5FU by continuous infusion (Meta-Analysis Group in Cancer
1998), or the administration of fluoropyrimidines through the
hepatic artery (Meta-Analysis Group in Cancer 1996) in case of
metastases confined to the liver. Each meta-analysis showed a
large increase in tumour response, without substantial impact on
survival. 
In the late 1980s, alpha-interferon (a-IFN) was proposed to
increase the efficacy of 5FU in advanced colorectal cancer. After
the initial report by Wadler et al (1989) of a tumour response rate
of 76% in a group of 17 previously untreated patients, additional
phase II trials of 5FU plus a-IFN with or without leucovorin were
undertaken (Pazdur et al, 1990); (Piedbois et al, 1991); (Weh et al,
1992); (Raderer and Scheithauer, 1995) followed by several
randomized phase III trials. Most randomized trials were disap-
pointing, but despite a total of 3500 patients enrolled in these
studies, there is to date no overall assessment of the true impact of
a-IFN in advanced colorectal cancer. We therefore decided to
explore this question through a meta-analytic approach based on
individual patient data. Toxicity was not studied, since at the time
of beginning the present analyses, individual trials had already
demonstrated that the addition of a-IFN to a 5FU regimen led to
an increased risk of toxicity. 
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Summary Two meta-analyses were conducted to quantify the benefit of combining a-IFN to 5FU in advanced colorectal cancer in terms of
tumour response and survival. Analyses were based on a total of 3254 individual patient data provided by principal investigators of each trial.
The meta-analysis of 5FU ± LV vs. 5FU ± LV + a-IFN combined 12 trials and 1766 patients. The meta-analysis failed to show any statistically
significant difference between the two treatment groups in terms of tumour response or survival. Overall tumour response rates were 25% for
patients receiving no a-IFN vs. 24% for patients receiving a-IFN (relative risk, RR = 1.02), and median survivals were 11.4 months for patients
receiving no a-IFN vs. 11.5 months for patients receiving a-IFN (hazard ratio, HR = 0.95). The meta-analysis of 5FU + LV vs. 5FU + a-IFN
combined 7 trials, and 1488 patients. This meta-analysis showed an advantage for 5FU + LV over 5FU + a-IFN which was statistically
significant in terms of tumour response (23% vs. 18%; RR = 1.26; P = 0.042), and of a borderline significance for overall survival (HR = 1.11;
P = 0.066). Metastases confined to the liver and primary rectal tumours were independent favourable prognostic factors for tumour response,
whereas good performance status, metastases confined to the liver or confined to the lung, and primary tumour in the rectum were
independent favourable prognostic factors for survival. We conclude that a-IFN does not increase the efficacy of 5FU or of 5FU + LV, and that
5FU + a-IFN is significantly inferior to 5FU + LV, for patients with advanced colorectal cancer. © 2001 Cancer Research Campaign
http://www.bjcancer.com
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Trial selection 
Two meta-analyses were conducted concomitantly. In the first one
we considered all properly randomised trials comparing 5FU with
or without folinic acid (5FU ± LV) to the same 5FU ± LV regimen
plus a-IFN (5FU ± LV + a-IFN). In the second meta-analysis we
considered all properly randomised trials comparing 5FU + LV to
5FU + a-IFN. In both meta-analyses, a-IFN must have consisted
of a-2a-interferon or a-2b-interferon, and patients must have been
included in the trial before July 1996. The search for relevant trials
was initiated in October 1996 by consulting MEDLINE, Physician
Data Query (PDQ), the proceedings of major conferences since
1989, and through contacts with principal investigators. A total of
20 relevant trials were identified, but 3 of them (335 patients)
could not be included in the meta-analysis, due to lack of data or
information on the trial (Kreuser et al, 1995); (Kosmidis et al,
1996); (Recchia et al, 1996). 
Meta-analysis of 5FU ± LV vs. 5FU ± LV + a-IFN (Table 1) 
The comparison of 5FU versus 5FU + a-IFN was addressed in 7
trials, the Roche International Clinical Research Center (RICRC)
trial (Greco et al, 1996), the Palermo trial (Palmeri et al, 1998), the
Ancona trial (Piga et al, 1996), two Royal Marsden Hospital
(RMH) trials (Hill et al, 1995a+b), the trial from France (Dufour
et al, 1996), and the Eastern Cooperative Oncology Group, Cancer
and Leukemia Group B (ECOG/CALGB) trial (O’Dwyer et al,
1996). The ECOG/CALGB trial (O’Dwyer et al, 1996) was not
considered in the first meta-analysis, because unlike the other
trials, the planned dose of 5FU and its mode of administration
were not the same in the 2 treatment groups. In most trials, the
5FU regimen was close to the Wadler regimen (Wadler et al,
1989), consisting of an initial 5-day 5FU infusion followed by a
weekly 5FU infusion. The dose of 5FU varied from 500 to 750
mg/m2/day. The dose of a-IFN varied from 3 to 10 MU, 3 times a
week. Based on the impact of the mode of 5FU administration on
tumour response and survival (Meta-Analysis Group In Cancer,
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Table 1 Randomised clinical trials comparing 5FU ± LV to 5FU ± LV + a-IFN in advanced colorectal cancer 
Comparison Patients Treatment arms 
5FU vs. 5FU + a-IFN, with 5FU bolus 
RICRC 245 5FU 750 mg/m2/d continuous infusion d1 to d5, then weekly on bolus 
Greco et al, 1996 Same + a-IFN 9 MU three times a week 
Palermo 169 5FU 750 mg/m2/d bolus d1 to d5; then weekly 
Palmeri et al, 1998 Same + a-IFN 9 MU three times a week 
Ancona 141 5FU 500 mg/m2/d bolus d1 to d5; then weekly 
Piga et al, 1996 Same + a-IFN 3 MU/d 
RMH 106 5FU 750 mg/m2/d continuous infusion d1 to d5; then weekly on bolus 
Hill et al, 1995a Same + a-IFN 10 MU three times a week 
France 106 5FU 750 mg/m2/d continuous infusion d1 to d5; then weekly on bolus 
Dufour et al, 1996 Same + a-IFN 9 MU three times a week 
Comparison Patients Treatment arms 
5FU vs. 5FU + a-IFN, with 5FU continuous infusion 
RMH PVI 160 5FU 300 mg/m2/d continuous infusion d1 to d70 followed by a 2 week-break 
Hill et al, 1995b Same + a-IFN 5 MU three times a week 
Comparison Patients Treatment arms 
5FU + LV vs. 5FU + LV + a-IFN, with 5FU bolus 
GOIM 204 5FU 375 mg/m2/d bolus d1 to d5, + l-folinic acid 100 mg/m2/d bolus d1 to d5 every 3 weeks 
Colucci et al, 1999 Same + a-IFN 3 MU/d d-2 to d5 
Roma 148 5FU 370 mg/m2/d bolus d1 to d5, + l-folinic acid 80 mg/m2/d bolus d1 to d5 every 4 weeks 
Cassano et al, 1996 Same + a-IFN 3 MU 3 times a week 
Hungary 73 5FU 425 mg/m2/d bolus d1 to d5 LV 20 mg/m2/d d1 to d5 every 4 weeks 
Pajkos et al, 1997 Same + a-IFN 3 MU three times a week 
Argentina 55 5FU 600 mg/m2/d bolus d1 to d5 + LV 500 mg/m2/d bolus d1 to d5 every 3 weeks 
Pensel et al, 1993 Same + a-IFN 5 MU/d, d1 to d5 every 3 weeks 
Comparison Patients Treatment arms 
5FU + LV vs. 5FU + LV + a-IFN, with 5FU continuous infusion 
MRC 260 5FU 800 mg/m2/d, (bolus + continuous infusion) d1 and d2, + LV 200 mg/m2/d bolus d1 and d2 every 2 weeks 
Seymour et al, 1996 Same + a-IFN 6 MU every other day d1 to d12 
AIO 99 5FU = 2 600 mg/m2/d IVC + LV = 500 mg/m2/d bolus, every week 
Köhne et al, 1998 same + IFN = 3 MIU/d, 3d/w 1998), trials were further stratified according to the duration of
5FU infusion. Bolus 5FU were administered in 5 comparisons
(Hill et al, 1995; Dufour et al, 1996; Greco et al, 1996; Piga et al,
1996; Palmeri et al, 1998) and continuous infusion 5FU in one
comparison (Hill et al, 1995b). 
The comparison of 5FU + LV versus 5FU + LV + a-IFN
was addressed in 6 trials, the Gruppo Oncologico dell’Italia
Meridionale (GOIM) trial (Colucci et al, 1999), the Roma trial
(Cassano et al, 1996), the trial from Hungary (Pajkos et al, 1997),
the trial from Argentina (Pensel et al, 1993), the Medical Research
Council (MRC) trial (Seymour et al, 1996), and the AIO trial
(Köhne et al, 1998). The AIO trial (Köhne et al, 1998) and the trial
from Hungary (Pajkos et al, 1997) were multiple-arm trials. Two
trials (MRC (Seymour et al, 1996), AIO (Köhne et al, 1998)) used
a continuous infusion 5FU. Trials were stratified according to 5FU
schedule of administration (5FU bolus and 5FU continuous infu-
sion), and in terms of modulation of 5FU by leucovorin. 
Meta-analysis of 5FU + LV vs. 5FU + a-IFN (Table 2) 
The comparison of 5FU + LV versus 5FU + a-IFN was addressed
in 7 trials, the Corfu-A trial (Corfu-A Study Group, 1995), the
GOIRC trial (Di Costanzo et al, 1995), the Yale trial (Marsh et al,),
the trial from Turkey (Aykan et al, 1996), the ECOG/CALGB trial
(O’Dwyer et al, 1996), the AIO trial (Köhne et al, 1998), the trial
Hungary (Pajkos et al, 1997). Three of these trials (O’Dwyer et al,
1996; Pajkos et al, 1997; Köhne et al, 1998) were multiple-arms
trials. 
In 4 trials same 5FU schedules were used in the 5FU/LV and in
the 5FU+IFN arms: 5FU bolus in the GOIRC (Di Costanzo et al,
1995), the Hungary (Pajkos et al, 1997), and the Turkey (Aykan
et al, 1996) trials, and 5FU continuous infusion in the AIO
(Köhne et al, 1998). In the 3 remaining trials (Corfu-A Study
Group, 1995); (Marsh et al) (O’Dwyer et al, 1996) 5FU consisted
of bolus injection in the 5FU/LV arm, and of continuous infusion in
the 5FU+IFN arm. Trials were therefore stratified according to 5FU
administration, i.e. same 5FU schedules in both arms (Di Costanzo
et al, 1995; Aykan et al, 1996, Pajkos et al, 1997; Kohne et al, 1998)
or 5FU bolus vs. 5FU continuous infusion (Corfu-A Study Group,
1995; (Marsh et al,) (O’Dwyer et al, 1996). 
Protocol for the meta-analysis 
In March 1997, all principal investigators received a protocol for
the meta-analyses, and were asked to provide individual patient
data. Information requested for every randomised patient was date
of randomisation, tumour measurability (i.e. measurable or non-
measurable tumours), treatment assigned by randomisation, age,
gender, performance status according to the ECOG scale, primary
tumour site (colon or rectum), prior adjuvant chemotherapy, prior
chemotherapy for metastatic disease, site of metastases, overall
response status with the first assigned treatment, date of response
or progression with the first allocated treatment, cross-over to
another treatment arm, date of death or last visit, survival status,
and cause of death if applicable. Data on toxicity were not
collected. 
Data collection 
All individual patient data were received by April 1999. Data were
extensively checked and discussed with all collaborators present at
a plenary meeting of the Meta-Analysis Group In Cancer held in
Atlanta, GA, in May 1999. 
Tumour response and survival 
Complete response (CR) and partial response (PR) criteria adopted
in individual trials followed the World Health Organization recom-
mendations (Miller et al, 1981) and were similar in all trials.
Patients experiencing minimal response, stable disease or progres-
sive disease were considered to have no response for the purpose
of the meta-analyses. In the MRC trial (Seymour et al, 1996) and
in the trial from Hungary (Pajkos et al, 1997) chemotherapy was
stopped after 6 months in the absence of tumour progression. In all
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Table 2 Randomised clinical trials comparing 5FU + LV to 5FU + a-IFN in advanced colorectal cancer 
Comparison Patients Treatment arms 
5FU + LV vs. 5FU + a-IFN, with the same dose of 5FU in both arms 
GOIRC 238 5FU 600 mg/m2 bolus, + l-folinic acid 250 mg/m2 bolus, + HU 3 g once a week for 6 weeks followed by a 2 week-break 
Di Costanzo et al, Same without l-folinic acid + l-folinic acid + a-IFN 3 MU three times a week 
1995
AIO 187 5FU 2 600 mg/m2 continuous infusion + LV 500 mg/m2 bolus, once a week for 6 weeks followed by a 2 week-break 
Köhne et al, 1998 Same without LV + a-IFN 3 MU three times a week 
Turkey 46 5FU 500 mg/m2/d bolus d1 to d5 + l-folinic acid 100 mg/m2, then weekly, every 4 weeks 
Aykan et al, 1996 Same without l-folinic acid + IFN 5 MU three times a week 
Comparison Patients Treatment arms 
5FU + LV vs. 5FU + a-IFN, with a higher dose of 5FU in the 5FU + a-IFN arm 
Corfu-A 496 5FU 370 mg/m2/d bolus, + LV 200 mg/m2/d d1 to d5 every 4 weeks 
Corfu-A Study  5FU 750 mg/m2/d continuous infusion d1 to d5, then weekly on bolus + a-IFN 9 MU three times a week 
Group, 1995
ECOG/CALGB 443 5FU 600 mg/m2/d bolus + LV 600 mg/m2 bolus once a week 
O’Dwyer et al, 1996 5FU 750 mg/m2/d continuous infusion d1 to d5, then weekly on bolus + a-IFN 9 MU three times a week 
Hungary 69 5FU 425 mg/m2/d bolus d1 to d5 LV 20 mg/m2/d d1 to d5 every 4 weeks 
Pajkos et al, 1997 5FU 750 mg/m2/d bolus d1 to d5 every 4 weeks + IFN 3 MU three times a week 
Yale 9 5FU 425 mg/m2/d bolus d1 to d5, + LV 20 mg/m2/d d1 to d5 every 4 weeks 
Marsh et al 5FU 750 mg/m2/d continuous infusion d1 to d5, then weekly on bolus + a-IFN 9 MU three times a weekother trials treatment was maintained until disease progression or
severe toxicity. Duration of survival was calculated from the date
of randomisation to the date of death, whatever its cause. 
Statistical methods 
The statistical methods for meta-analyses based on individual
patient data have been described in detail in previous publications
(ACCMP, 1992; ACCMP, 1994; MAGIC, 1996; MAGIC, 1998a;
MAGIC, 1998b). All analyses were based on an intention to treat
basis, without any patient exclusion. Tumour responses were
compared through relative risks (RR) in individual trials and
overall (MAGIC, 1998b). Prognostic factors for response were
identified through a logistic regression model (Cox, 1970).
Survival times were compared through hazard ratios (HR) in indi-
vidual trials and overall (Peto et al, 1977). Prognostic factors for
survival were identified through a proportional hazards regression
model (Cox, 1972). All P values were two-sided. 
RESULTS 
Patient characteristics 
A total of 3254 were included in the analyses. The main patient
characteristics are listed in Table 3 and 4. As could be expected in
large series of patients, there was no imbalance between the
experimental and the control groups for either of the comparisons
of interest. 84% of patients had died at the time of analysis. 
Meta-analysis of 5FU ± LV vs. 5FU ± LV + a-IFN 
1766 patients were included in this meta-analysis. The MRC trial
(Seymour et al, 1996), the trial from Argentina (Pensel, 1993), and
the trial from Ancona (Piga et al, 1996) allowed the inclusion of
patients with non-measurable disease. After exclusion of these
patients, 1683 patients were eligible for tumour response assess-
ment. Relative risks for individual trials and overall are presented
in Figure 1. Tumour response rates were 18% (70/387) for patients
allocated to 5FU bolus alone and 21% (80/376) for patients alloc-
ated to 5FU bolus + a-IFN (RR = 0.86; 95%CI = 0.65–1.15). In
the only trial using 5FU alone continuous infusion (Hill et al,
1995b), tumour response rate was 34% (27/80) for 5FU alone and
22% (18/80) for 5FU + a-IFN (RR = 1.50; 95% CI = 0.89–2.5). 
Tumour response rates were 26% (59/227) for patients allocated
to 5FU bolus + LV vs. 25% (59/233) for patients allocated to 5FU
bolus + LV + a-IFN (RR = 0.99; 95% CI = 0.72–1.35), and 34%
(52/151) for patients allocated to 5FU C.I + LV vs. 30% for
patients allocated to 5FU C.I. + LV + a-IFN (RR = 1.14; 95% CI =
0.81–1.59). The overall tumour response rates were 25%
(208/845) for 5FU ± LV, and 24% (202/838) for 5FU ± LV + a-
IFN (RR = 1.02; 95% CI = 0.87–1.2; P = 0.8), showing no advant-
age for a-IFN administration. 
There was no statistically significant survival difference
between 5FU and 5FU + a-IFN, nor between 5FU + LV and 5FU
+ LV + a-IFN (Figure 2). The overall survival hazard ratio for the
meta-analysis of 5FU ± LV versus 5FU ± LV + a-IFN was 0.95
(95% CI = 0.86–1.05; P = 0.33), showing no advantage for a-IFN
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Table 3 Patient characteristics: 5FU+/2LV vs. 5FU+/2LV+IFN 
Trial Accrual Trt. No. of Adjuvant Primary PS<2 Metastases (%) 
period  patients chemo. (%) colon (%) (%) Liver only Lung only 
RICRC 1989–92 5FU 124 0 NA 83 62 9 
Greco et al, 1996 5FU+IFN 121 0 NA 92 63 4 
Palermo 1990–93 5FU 88 0 100 95 62 3 
Palmeri et al, 1998 5FU+IFN 81 0 100 97 61 0 
Ancona 1990–93 5FU 72 3 75 97 44 6 
Piga et al, 1996 5FU+IFN 69 3 72 97 45 6 
RMH 1990–92 5FU 54 0 63 87 28 2 
Hill et al, 1995a 5FU+IFN 52 0 71 77 19 13 
France 1990–93 5FU 50 0 73 100 52 6 
Dufour et al, 1996 5FU+IFN 56 0 73 100 48 11 
RMH PVI 1992–94 5FU 80 0 81 58 19 9 
Hill et al, 1995b 5FU+IFN 80 0 70 60 19 9 
GOIM 1991–94 5FU/LV 101 0 56 88 41 7 
Colucci et al, 1999 5FU/LV+IFN 103 1 66 95 40 2 
Roma 1990–96 5FU/LV 73 0 67 79 17 3 
Cassano et al, 1996 5FU/LV+IFN 75 0 71 81 10 3 
Hungary 1993–96 5FU/LV 35 0 47 74 60 0 
Pajkos et al, 1997 5FU/LV+IFN 38 0 66 76 39 3 
Argentina 1990–91 5FU/LV 28 0 61 57 43 0 
Pensel et al, 1993 5FU/LV+IFN 27 0 59 59 41 7 
MRC 1991–93 5FU/LV 132 1 69 74 43 3 
Seymour et al, 1996 5FU/LV+IFN 128 1 67 76 36 5 
AIO 1992–93 5FU/LV 50 10 46 94 34 0 
Köhne et al, 1998 5FU/LV+IFN 49 6 51 96 44 4 
Total 1989–96 5FU+/-LV 887 1 70 98 43 5 
5FU+/-LV+IFN 879 1 71 98 40 5 
NA = not available. administration. Median survivals were 11.4 months for patients
treated without a-IFN, and 11.5 months for patients treated with
a-IFN. 
Meta-analysis of 5FU + LV vs. 5FU + a-IFN 
1488 patients were included in this meta-analysis. 
The ECOG/CALGB trial (O’Dwyer et al 1996) allowed the
inclusion of patients with non-measurable disease. After exclusion
of these patients, 1305 patients were eligible for tumour response
assessment. 
Tumour response rates were 23% (152/655) for patients alloc-
ated to 5FU + LV vs. 18% (115/650) for patients allocated to 5FU
+ a-IFN. The overall tumour response RR was 1.26 (95% CI =
1.01–1.59; P = 0.042), showing a statistically significant advant-
age for 5FU + LV over 5FU + a-IFN (Figure 3). However, the
heterogeneity between trials in this meta-analysis was rather
important (P value for heterogeneity, P = 0.001), mostly between
trials using the same 5FU schedules in both treatment arms
(P value for heterogeneity, P = 0.003). 
Analyses stratified by type of 5FU administration showed that
the advantage of 5FU + LV over 5FU + a-IFN was limited to the
group of trials using the same 5FU schedules in both treatment
arms (RR = 1.80; 95% CI = 1.29–2.51; P = 0.0005). 
Survival analysis showed a small trend in favour of 5FU + LV
over 5FU + a-IFN, but this advantage was not statistically
significant (overall HR = 1.11; 95% CI = 0.99–1.24; P = 0.066)
(Figure 4). Median survivals were 11.7 months for patients allo-
cated to 5FU + LV and 11.3 months for patients allocated to 5FU +
a-IFN. The survival difference reached statistical significance in
the group of trials using the same 5FU schedules in both treatment
arms (HR = 1.29; 95% CI 1.07–1.57; P = 0.008). There was some
heterogeneity in this group of trials, but which did not reach a
statistically significant level (P = 0.67). 
Prognostic factor analyses 
Individual patient data used for the two meta-analyses were
combined to identify prognostic factors for response and survival
(3254 patients). Sex, age, performance status (PS), primary tumour
site, previous adjuvant chemotherapy, metastatic site, and allocated
treatment (no a-IFN vs. a-IFN) were considered in these analyses.
In a logistic regression model, metastases confined to the liver
(P < 10-4), and primary rectal tumours (P = 0.042) were the inde-
pendent favourable prognostic factors for tumour response.
Tumour response rates were 26% for patients with metastases
confined to the liver versus 20% for the others. Patients with rectal
cancer had a 26% tumour response rate, vs. 22% with colon
tumour. 
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Table 4 Patient characteristics: 5FU+LV vs. 5FU+IFN 
Trial Accrual Trt. No.of Adjuvant Primary PS<2 Metastases (%) 
Period  Patients Chemo. (%) colon (%) (%) Liver only Lung only 
Corfu-A 1989–91 5FU/LV 250 0 NA 83 38 4 
Corfu-A Study Group, 1995 5FU+IFN 246 0 NA 83 37 4 
ECOG 1990–95 5FU/LV 224 12 68 92 37 11 
O’Dwyer et al, 1996 5FU+IFN 219 11 73 95 35 9 
AIO 1992–95 5FU/LV 93 12 50 96 44 4 
Köhne et al, 1998 5FU+IFN 94 11 61 92 39 7 
GOIRC 1992–94 5FU/LV 119 0 64 98 56 4 
Di Costanzo et al, 1995 5FU+IFN 119 0 59 97 59 5 
Hungary 1993–96 5FU/LV 35 0 47 74 60 0 
Pajkos et al, 1998 5FU+IFN 34 0 53 79 50 3 
Turkey 1992–94 5FU/LV 19 15 50 72 21 0 
Aykan et al, 1996 5FU+IFN 27 15 21 62 37 11 
Yale 1990–91 5FU/LV 4 0 75 100 25 25 
Marsh et al 5FU+IFN 5 0 100 80 60 0 
Total 1989–96 5FU/LV 744 6 61 89 42 6 
5FU+IFN 744 5 64 89 41 6 
NA = not available. 
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Figure 1 Tumour response relative risks in individual trials and overall for
the meta-analysis 5FU ± LV vs. 5FU ± LV + a-IFN In a Cox regression model, good PS (P < 10-4), metastases
confined to the liver or confined to the lung (P = 0.0002 and P =
0.004 respectively), and primary tumour in the rectum (P = 0.003)
were the independent favourable prognostic factors for survival.
One-year survival was 59% for patients with PS 0, 47% for
patients with PS 1, and 30% for patients with PS 2 or worse; 54%
for patients with metastases confined to the liver, 46% for the
others; 61% for patients with metastases confined to the lung, 49%
for the others; 56% for patients with primary rectal cancer, 47%
for the others. 
DISCUSSION 
Pre-clinical studies indicate that a-IFN may increase the cytotoxi-
city of 5FU in a variety of tumour cell lines (Elias and Crissman,
1988; Wadler et al, 1990). Several mechanisms of interaction
between 5FU and interferon have been demonstrated. In vitro data
published by Elias and Crissman (Elias and Crissman, 1988)
suggest that the enzyme thymidylate synthase might be a target for
this interaction. Moreover, the presence of thymidine in the culture
medium tends to block the synergic effect (Neefe and John, 1991).
Interferon may also modify the plasma pharmacokinetics of 5FU
(Lindley et al, 1990; Danhouser et al, 1991). Finally, 5FU may
influence the immunomodulatory actions of interferon (Neefe and
John, 1991). However, despite more than 3000 patients included in
randomized trials, the clinical impact of combining a-IFN to 5FU
remained debatable. 
The 2 meta-analyses presented here address the efficacy of
a-IFN combined with 5FU in advanced colorectal cancer. Tumour
response rate and survival were the two main end points. Toxicity
was not studied, since at the time of beginning these meta-analyses
individual trials had already demonstrated that the addition of
a-IFN to a 5FU regimen led to an increased risk of neutropenia,
mucositis, and neurotoxicity, and was associated with flu-like
syndromes. a-IFN also produced a significant impairment of
quality of life in the MRC trial (Seymour et al, 1996). 
The meta-analysis of trials comparing 5FU ± LV to a similar
5FU regimen plus a-IFN failed to show any difference between
control and experimental arms in terms of tumour response or
survival. The tumour response rate with 5FU bolus alone reported
in the group of trials comparing 5FU to 5FU + a-IFN was rather
high (19%), compared to tumour responses reported for patients
receiving 5FU bolus in the 4 meta-analyses previously performed
by our group, which varied between 11% and 14% (ACCMP,
1992, 1994; MAGIC, 1996, 1998a). This may reflect a selection of
patients with favourable prognostic characteristics in trials
included in the present meta-analysis, but does not invalidate our
finding of no difference between 5FU alone and 5FU + a-IFN. It
should also be noted that the doses of 5FU delivered in the 5FU
alone arms were generally high compared with the 5FU doses
reported in our previous meta-analyses. 
In contrast, the meta-analysis of trials comparing 5FU + LV to
5FU + a-IFN showed higher response rates and a trend towards
longer survival in favour of 5FU + LV. In this set of trials, the
overall tumour response rate and the median survival of patients
receiving 5FU + LV (23% and 13 months, respectively) were
remarkably similar to those reported previously in the meta-
analysis of trials comparing 5FU to 5FU + LV (ACCMP, 1992),
(23% and 11.5 months, respectively). Thus, the advantage of 5FU
+ LV over 5FU + a-IFN observed in the present meta-analysis
does not seem to be due to some selection bias that might have
favoured patients allocated to the 5FU + LV arm. 
In this meta-analysis, the stratification of trials by type of 5FU
administration (Figures 3 and 4) showed a statistically significant
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(d) 5FU/LV CI
MRC 107 / 128 3.5 53.0 108 / 132
AIO 43 / 49 -0.2 20.3 41 / 50
Subtotal 150 / 177 3.3 73.2 149 / 182
Total 754 / 879 -18.6 362.9 744 / 887
(c) 5FU/LV bolus
GOIM 93 / 103 1.0 45.7 91 / 101
Roma 55 / 75 -2.0 27.0 55 / 73
(b) 5FU CI
RMH PVI 73 / 80 6.6 34.4 66 / 80
Subtotal 73 / 80 6.6 34.4 66 / 80
Hungary 38 / 38 -9.8 15.8 35 / 35
Argentina 23 / 27 -5.8 11.5 26 / 28
Subtotal 209 / 243 -16.7 100.0 206 / 237
(a) 5FU bolus
RICRC 89 / 121 -2.8 44.5 91 / 124
study O/N O-E V 5FU+/-LV+IFN
5FU+/-LV+IFN
O/N
5FU+/- LV
5FU+/-LV (SE)
Hazard ratio Hazard redn.
Palermo 64 / 81 -6.9 32.5 71 / 88
Ancona 62 / 69 -1.5 30.1 60 / 72
RMH 52 / 52 7.8 24.4 52 / 54
France 55 / 56 -8.4 23.8 49 / 50
Subtotal 322 / 379 -11.8 155.3 323 / 388
test of treatment effect X 
2
1
= 0.95, P = 0.33
test of heterogeneity X 
2
  
11
= 16.96, P = 0.11
0.0
IFN better      /      IFN worse
2.0 1.0
5% (5%)
-5% (13%)
15% (9%)
-21% (22%)
7% (8%)
Figure 2 Survival hazard ratios in individual trials and overall for the
meta-analysis 5FU ± LV vs. 5FU ± LV + a-IFN 
(d) 5FU bolus vs CI
Corfu-A 50 / 246 20 % 18 % 45 / 250
ECOG 19 / 125 15 % 16 % 22 / 135
Yale 0 / 5 0 % 0 % 0 / 4
Subtotal 69 / 376 18 % 17 % 67 / 389
Total 115 / 650 18 % 23 % 152 / 655
(a) 5FU same schedules
GOIRC 10 / 119 8 % 27 % 32 / 119
Study % % 5FU+IFN : 5FU/LV N O/N
5FU+IF
O/N
5FU/LV Relative risk
AIO 16 / 94 17 % 43 % 40 / 93
Hungary 13 / 34 38 % 26 % 9 / 35
Turkey 7 / 27 26 % 21 % 4 / 19
Subtotal 46 / 274 17 % 32 % 85 / 266
test of treatment effect X 
2
1
= 4.1, P = 0.042
test of heterogeneity X 
2
 
6
= 22.36, P = 0.001
.05
IFN better      /      IFN worse
12 0 .1 .2 .5 10 5 2
1.26
0.94
1.80
Figure 3 Tumour response relative risks in individual trials and overall for
the meta-analysis 5FU + LV vs. 5FU + a-IFN 
(d) 5FU bolus vs CI
Corfu-A 186 / 246 91.6
ECOG 207 / 219 104.2
Yale 5 / 5 2.0
Subtotal 398 / 470 197.8
Total 626 / 744 303.4
(a) 5FU same schedules
GOIRC 101 / 119 48.3
study 5FU+IFN 5FU/LV (SE) O/N
5FU+IFN
O/N O-E V
5FU/LV Hazard ratio Hazard redn.
AIO 80 / 94 36.4
Hungary 34 / 34 15.9
Turkey 13 / 27 5.0
Subtotal 228 / 274
2.5
2.6
-0.2
4.8
32.1
10.3
14.3
3.3
-0.7
27.3 105.6
185 / 250
212 / 224
4 / 4
401 / 478
611 / 744
95 / 119
70 / 93
35 / 35
10 / 19
210 / 266
test of treatment effect X 
2
1
= 3.39 , P = 0.066
test of heterogeneity X 
2
 
6
= 5.39 , P = 0.495
0.0
IFN better      /      IFN worse
1.0 2.0
-11% (7%)
-2% (8%)
-29% (13%)
Figure 4 Survival hazard ratios in individual trials and overall for the 
meta-analysis 5FU + LV vs. 5FU + a-IFN advantage of 5FU/LV over 5FU+IFN in the group of trials using
the same 5FU schedules in both arms. By contrast, there was no
difference between the two treatment arms when 5FU was admin-
istered by bolus in the 5FU/LV arm and by continuous infusion in
the 5FU + IFN. This could be linked to the tumour response and
survival advantage of 5FU continuous infusion over 5FU bolus
demonstrated in one of our previous meta-analyses (MAGIC,
1998a). 
5FU dose intensity is not a valid parameter when comparing
bolus versus infusion or mixed regimens. Consequently, no
attempt was made to stratify trials according to 5FU dose intensity. 
The prognostic factor analysis confirms well-established results,
such as the key role of performance status for survival. Other find-
ings are less classical, such as the role of primary and metastatic
tumour sites, and are currently under investigation by our group,
on the basis of 7000 individual patient data with advanced
colorectal cancer. In the adjuvant setting, a trial conducted by the
National Surgical Adjuvant Breast and Bowel Project (NSABP-
C05) also failed to show any advantage for 5FU + LV + a-IFN
over 5FU + LV in patients with stage II-III colon cancer (Wolmark
et al, 1998). On-going studies are currently addressing the interest
of other types of interferon, such as a-2c IFN and b-IFN (Villar
Grimalt et al, 1999). However, new agents, such as CPT-11
(irinotecan) (Douillard et al, 2000; Saltz et al, 2000) or oxaliplatin
(de Gramont et al, 2000) have demonstrated clinical benefits in
advanced colorectal cancer, and are therefore more plausible
candidates for the adjuvant setting. 
We conclude that a-IFN does not increase the efficacy of 5FU in
advanced colorectal cancer, and should not be offered in routine
clinical practice. 
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